Former X CEO Linda Yaccarino takes eMed top job
Aug. 5 (UPI) -- The eMed Population Health digital health platform announced Tuesday that former X Chief Executive Officer Linda Yaccarino has been appointed its new CEO.
"Yaccarino's hiring is a game changing moment in eMed's mission to make safe, effective, and sustainable chronic care accessible directly through an all-in-one, digital-first experience," eMed said in a press release. "Her unparalleled experience in leading paradigm shifting transformations will bring a new dimension to the company."
Yaccarino had stepped down from her post at X in July after a two-year stint without an explanation, but her resignation came a day after the X chatbot Grok had gone on an anti-Semitic tirade.
EMed is currently at work on a population health management platform for the GLP-1 weight loss and diabetes drugs. Goldman Sachs researchers have estimated that about 15 million adults in the United States alone may be treated with anti-obesity medications, or AOMs by 2030, and that the industry could reach $100 billion in annual revenue by that year.
"The healthcare industry has been disrupted by technology, but not yet completely transformed by it," Yaccarino said in the release. "There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
20 minutes ago
- Business Insider
Elon Musk says X plans to introduce ads to Grok to 'pay for those expensive GPUs'
Elon Musk says he is planning to introduce ads on xAI's chatbot Grok. The billionaire entrepreneur said that ads could display when users ask the chatbot about a problem, promoting products and services that offer a "specific solution" to that problem. "There will be that opportunity in Grok's suggestions," Musk said during a Wednesday livestream on X. He also said that ads could help pay for the chips, known as graphics processing units, that power Grok. "Our focus thus far has just been on making Grok the smartest, most accurate AI in the world, and I think we've largely succeeded in that. So we'll turn our attention to 'how do we pay for all those expensive GPUs?'," Musk said. Musk did not provide a timeline for introducing ads into Grok's suggestions. The billionaire entrepreneur's comments came during an "ask me anything" discussion with advertisers, in which Musk outlined new AI tools for automating ad tasks on X to help match consumers with relevant products. Musk said Grok was "good enough" for advertisers to "be able to upload an ad and do nothing else." In March, xAI acquired X, which both belong to Musk, for $33 billion, and the companies have since become increasingly intertwined. Musk also said that ads would have to meet some minimum aesthetic requirements. "We're not saying that an ad has to be a complete work of art, but it can't be an eyesore," said Musk. The overture to advertisers came a month after Linda Yaccarino stepped down as the CEO of X. Yaccarino's appointment in 2023 was heralded as a smart move by the advertising industry, but she soon found herself fighting to keep advertisers from leaving the platform after a string of content moderation controversies on X. Grok, too, has faced controversy in recent months, with xAI apologizing after a new set of directives caused the chatbot to make inflammatory comments on X that included antisemitic jokes and praising Adolf Hitler.
Yahoo
24 minutes ago
- Yahoo
Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its much-awaited oral GLP-1 pill sent the stock lower in early trading. The stock is down 4% year to date, even as the sales of its blockbuster GLP-1s drive growth. Eli Lilly reported $15.56 billion in revenue, beating Wall Street estimates of $14.69 billion. Earnings per share came in at $6.31, compared to Street expectations of $5.56. Revenue in the US alone was $10.81 billion, driven by a 46% increase in volume of sales of GLP-1 drugs, Mounjaro and Zepbound. But the potential revenue could have been higher if not for an 8% decline in prices, according to Lilly. Though the pharma giant has a diverse portfolio of sales drivers, attention has been placed on the competitive GLP-1 space, as its weight-loss drug Zepbound has overtaken competitor and first-mover, Novo Nordisk's (NVO) Wegovy. The latest GLP-1 prescription data tracked by JPMorgan analysts shows prescriptions for Zepbound have increased 225% year over year, with total weekly prescriptions at more than 418,000 as of the end of July — compared to Wegovy's 35% year-over-year growth and 281,000 total weekly prescriptions. Meanwhile, what investors had viewed as the next ace in its pipeline, a GLP-1 pill called orforglipron, disappointed in late-stage trials. The company reported a 25% patient drop-out at the highest dose. "The discontinuation rate on the placebo was also quite high (press release says 29%), which makes us think there was something about the study that is odd/unique and will need to get some clarity here," Mizuho's healthcare expert Jared Holz wrote. "To have this many patients drop out across arms is surprising and almost does not compute." The company has been inching toward an FDA decision on the pill. The data for the pill will be filed with the FDA this year, and Eli Lilly expects it could get to market by next year. Lilly's results come a day after disappointing results from Novo Nordisk, which has faced pressure from compounders as well as the competition from Eli Lilly. Novo Nordisk revised its 2025 outlook to account for slower US sales. Eli Lilly, meanwhile, has seen strong growth, especially with new prescriptions of GLP-1s in the US moving more favorably toward Eli Lilly — more than 60% of new weight-loss prescriptions are for Zepbound, according to the latest data tracked by analysts. CEO Dave Ricks said in a statement, "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28 minutes ago
- Yahoo
Hobby stays hot: Record $308 million spent online on cards in July
More than $308 million was spent on sports and trading cards online in July to set an industry record for the second consecutive month. The highest mark recorded by data tool Card Ladder, July's total eclipses the previous record of $306 million from June. Prior to June, March was the highest recorded month in Card Ladder's database with $303 million in total transactions. The record total can continue to rise as previously unrecorded sales from July are retroactively added to the database. It also doesn't include in-person sales from shows such as the National Sports Collectors Convention, which reported record attendance last week. More than 5.5 million total transactions were logged by Card Ladder in July, the second-most recorded in the tool's database behind only the 5.6 million recorded in March. The record month was largely driven by eBay, which had more than $266 million in sales recorded by Card Ladder. Fanatics Collect had the second-highest total with just under $23 million. Heritage finished with roughly $10.5 million, while Alt sold $7.3 million. Caitlin Clark's 2024 Panini Rookie Royalty WNBA Flawless Logowoman 1/1 was the most expensive card to sell in July after fetching $660,000 in Fanatics Collect's July Premier Auction. That result is the highest ever for a women's sports card at public auction. Third-party grading tracker GemRate reported 2.3 million cards were graded in July. That total is up 10% compared to June and 34% year-over-year. Ben Burrows is a reporter and editor for cllct, the premier company for collectible culture. He was previously the Collectibles Editor at Sports Illustrated. You can follow him on X and Instagram @benmburrows.
